{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=recombinant+C1+inhibitor",
    "query": {
      "intervention": "recombinant C1 inhibitor"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=recombinant+C1+inhibitor&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T12:22:34.324Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01359969",
      "title": "Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "rhC1INH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "13 Years",
        "sex": "ALL",
        "summary": "2 Years to 13 Years"
      },
      "enrollment_count": 57,
      "start_date": "2012-01-17",
      "completion_date": "2017-07-17",
      "has_results": true,
      "last_update_posted_date": "2024-03-29",
      "last_synced_at": "2026-09-24T12:22:34.324Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01359969"
    },
    {
      "nct_id": "NCT02663687",
      "title": "Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hereditary Angioedema (HAE)"
      ],
      "interventions": [
        {
          "name": "Recombinant human C1 esterase inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SHP623",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 48,
      "start_date": "2016-02-19",
      "completion_date": "2016-12-05",
      "has_results": true,
      "last_update_posted_date": "2021-06-03",
      "last_synced_at": "2026-09-24T12:22:34.324Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02663687"
    },
    {
      "nct_id": "NCT03576469",
      "title": "A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "CVI - Common Variable Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "C1-esterase inhibitor [recombinant] (C1-INH-R)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "IMMUNOe Research Centers",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-06-13",
      "completion_date": "2020-03-01",
      "has_results": false,
      "last_update_posted_date": "2021-02-15",
      "last_synced_at": "2026-09-24T12:22:34.324Z",
      "location_count": 1,
      "location_summary": "Centennial, Colorado",
      "locations": [
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03576469"
    },
    {
      "nct_id": "NCT04198766",
      "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Non-Small Cell Lung Cancer",
        "Head and Neck Cancer",
        "Melanoma",
        "Gastric Cancer",
        "Renal Cell Carcinoma",
        "Urothelial Carcinoma",
        "Resectable Non-Small-Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "INBRX-106 - Hexavalent OX40 agonist antibody",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab 200 mg",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin AUC-5",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin AUC-6",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed 500 mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin 75mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel 200mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Nab paclitaxel 100mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine (1000 mg/m2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inhibrx Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 340,
      "start_date": "2019-12-10",
      "completion_date": "2033-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-09-24T12:22:34.324Z",
      "location_count": 30,
      "location_summary": "Duarte, California • Glendale, California • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04198766"
    },
    {
      "nct_id": "NCT01188564",
      "title": "Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "rhC1INH",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2011-01",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2015-08-07",
      "last_synced_at": "2026-09-24T12:22:34.324Z",
      "location_count": 15,
      "location_summary": "Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188564"
    },
    {
      "nct_id": "NCT01035593",
      "title": "Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Rejection",
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "plasmapheresis and IVIG",
          "type": "PROCEDURE"
        },
        {
          "name": "recombinant C1 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2010-12",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2012-02-17",
      "last_synced_at": "2026-09-24T12:22:34.324Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01035593"
    },
    {
      "nct_id": "NCT03697187",
      "title": "Patient Registry to Evaluate the Real-world Safety of Ruconest®",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "rhC1INH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 152,
      "start_date": "2018-06-30",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2024-04-05",
      "last_synced_at": "2026-09-24T12:22:34.324Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03697187"
    },
    {
      "nct_id": "NCT06690047",
      "title": "Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "Ruconest",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bernstein Clinical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-08-14",
      "completion_date": "2022-04-28",
      "has_results": false,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-09-24T12:22:34.324Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06690047"
    },
    {
      "nct_id": "NCT01756157",
      "title": "Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema (HAE)"
      ],
      "interventions": [
        {
          "name": "CINRYZE with rHuPH20",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2013-02-04",
      "completion_date": "2013-09-13",
      "has_results": true,
      "last_update_posted_date": "2021-06-03",
      "last_synced_at": "2026-09-24T12:22:34.324Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01756157"
    },
    {
      "nct_id": "NCT04530136",
      "title": "Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Confirmed Coronavirus Disease"
      ],
      "interventions": [
        {
          "name": "Ruconest",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 38,
      "start_date": "2020-11-30",
      "completion_date": "2021-12-01",
      "has_results": true,
      "last_update_posted_date": "2024-02-16",
      "last_synced_at": "2026-09-24T12:22:34.324Z",
      "location_count": 4,
      "location_summary": "Marlton, New Jersey • Mount Holly, New Jersey • Ridgewood, New Jersey + 1 more",
      "locations": [
        {
          "city": "Marlton",
          "state": "New Jersey"
        },
        {
          "city": "Mount Holly",
          "state": "New Jersey"
        },
        {
          "city": "Ridgewood",
          "state": "New Jersey"
        },
        {
          "city": "Voorhees Township",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04530136"
    }
  ]
}